THE RELATIONSHIP OF INTESTINAL MICROBIOTA WITH POLYCYSTIC OVARY SYNDROME (PCOS)

• Autor(a) principal: Camilo Heidmann Soccol, Marcilene
• Data de Publicação: 2022
• Outros Autores: Rippel Silveira, Márcia Liliane, Webber Dimer, Nádia
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Scientia Generalis
• Texto Completo: https://scientiageneralis.com.br/index.php/SG/article/view/406
• topic: Síndrome dos ovários policísticos; Microbiota intestinal; Disbiose intestinal; Probióticos; Prebióticos; Síndrome de ovario poliquístico; Microbiota intestinal; Disbiosis intestinal; Probióticos; Prebióticos; Polycystic ovary syndrome; Intestinal microbiota; Intestinal dysbiosis; Probiotics; Prebiotics

Polycystic ovary syndrome (PCOS) is a widespread endocrine disease, affecting 6% to 20% of women of reproductive age worldwide. Studies have shown the gut microbiota to be a key factor in the development of PCOS, playing an important role in many disorders of the disease. This study aimed to carry out a literature review seeking to understand the role of the intestinal microbiota in the pathogenesis of PCOS and the effects of probiotic, prebiotic and symbiotic supplementation in the treatment of the syndrome. This is a bibliographic review study based on a qualitative analysis of the literature from the selection of articles published in scientific journals indexed in databases such as PubMed, SciELO, MEDLINE and LILACS, focused on publications related to polycystic ovary syndrome, intestinal microbiota and intestinal dysbiosis, published in the last years. Recent studies in humans and rodent models have shown that intestinal dysbiosis may contribute to the development of PCOS by influencing the lipopolysaccharide (LPS) pathways, intestinal permeability, choline, bile acids and the gut-brain axis. It is well established that PCOS is characterized by a chronic state of inflammation and insulin resistance. As part of the treatment of PCOS, methods are suggested that aim to modulate the intestinal microbiota, such as probiotic, prebiotic and symbiotic agents, and that these products can serve as new options in the management of PCOS, in order to correct the signs and symptoms of the disease.